http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Electro-acupuncture and Chinese herbs for treatment ofcervical intervertebral disk disease in a dog
Ayne Murata Hayashi,J?lia Maria Matera,,Tatiana Soares da Silva,Ana CarolinaBrand?o de Campos Fonseca Pinto,S?lvia Renata Gaido Cortopassi 대한수의학회 2007 Journal of Veterinary Science Vol.8 No.1
A non-ambulatory dog with tetraparesis following a pain episode that had evolved over 2 months was submitted for medical treatment and diagnosed with intervertebral disk disease at C3-C4 and dorsal extradural compression at C1-C2 and C3-C4 using myelography and computed tomography. The dog experienced ambulation recovery after 15 days of treatment with only electroacupuncture and Chinese herbal medicine, with marked improvement occurring after only 10 treatments. Six months of followup demonstrated that the dog was stable and had no recurrence of symptoms. Therefore, it was concluded that the combination of electroacupuncture and Chinese herbal medicine was responsible for motor rehabilitation.
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
Nadia Marascio,Angela Quirino,Giorgio Settimo Barreca,Luisa Galati,Chiara Costa,Vincenzo Pisani,Maria Mazzitelli,Giovanni Matera,Maria Carla Liberto,Alfredo Focà,Carlo Torti 대한간학회 2019 Clinical and Molecular Hepatology(대한간학회지) Vol.25 No.1
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.